Q: What therapeutic areas does University of Michigan Rogel Cancer Center research focus on?

University of Michigan Rogel Cancer Center clinical trials span Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

Question 1

How many clinical trials has University of Michigan Rogel Cancer Center sponsored?

Accepted Answer

ClinicalMetric currently tracks 11 clinical trials sponsored by University of Michigan Rogel Cancer Center, of which 11 are actively recruiting participants. These trials cover conditions including Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Diffuse Large B-Cell Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

Question 2

What therapeutic areas does University of Michigan Rogel Cancer Center research focus on?

Accepted Answer

University of Michigan Rogel Cancer Center is a clinical research sponsor with 11 registered studies on ClinicalTrials.gov, of which 11 are actively recruiting participants. Research covers conditions including Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma.

The trial portfolio spans Phase 1, Phase 2, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Question 3

How do I participate in a University of Michigan Rogel Cancer Center clinical trial?

Accepted Answer

To participate in a University of Michigan Rogel Cancer Center trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all University of Michigan Rogel Cancer Center trials with current recruitment status updated daily.

University of Michigan Rogel Cancer Center

Frequently Asked Questions — University of Michigan Rogel Cancer Center

Clinical Trials by University of Michigan Rogel Cancer Center

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy

A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe

Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

Metastatic Leiomyosarcoma Biomarker Protocol

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas